Andexanet Alfa
Basic Information
| Item | Value |
|---|---|
| DrugBank ID | DB14562 |
| Evidence Level | L5 (Computational Prediction) |
| Number of Predicted Indications | 21 |
Predicted Indications (TxGNN)
The following are potential new indications predicted by the TxGNN model. Higher scores indicate higher predicted relevance.
| # | Indication | Source |
|---|---|---|
| 1 | Glanzmann thrombasthenia | KG + DL |
| 2 | primary release disorder of platelets | KG + DL |
| 3 | pseudo-von Willebrand disease | KG + DL |
| 4 | hemophilia | KG + DL |
| 5 | hemorrhagic disorder due to a constitutional thrombocytopenia | KG + DL |
| 6 | bleeding diathesis due to a collagen receptor defect | KG + DL |
| 7 | acquired coagulation factor deficiency | KG + DL |
| 8 | Scott syndrome | KG + DL |
| 9 | congenital prothrombin deficiency | KG + DL |
| 10 | hereditary thrombocytosis with transverse limb defect | KG + DL |
| 11 | familial thrombomodulin anomalies | KG + DL |
| 12 | flood factor deficiency | KG + DL |
| 13 | fetal and neonatal alloimmune thrombocytopenia | KG + DL |
| 14 | platelet-type bleeding disorder | KG + DL |
| 15 | methylcobalamin deficiency type cblG | KG + DL |
| 16 | autosomal dominant macrothrombocytopenia | KG + DL |
| 17 | drug-induced osteoporosis | KG + DL |
| 18 | Ehlers-Danlos syndrome, fibronectinemic type | KG + DL |
| 19 | renal osteodystrophy | KG + DL |
| 20 | inherited thrombophilia | KG + DL |
| 21 | hemorrhagic disease of newborn | KG + DL |
Disclaimer
These predictions are for research purposes only and do not constitute medical advice. Clinical validation is required before any clinical application.